Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANE-Uganda Phase Ib sildenafil dose-finding trial after birth asphyxia
PACTR202202647130754Phase 1Not yet recruiting
- Sponsor
- Research Institute of the McGill University Health Centre
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sildenafil in hypoxic-ischemic encephalopathy (HIE) and asphyxia neonatorum, sponsored by Research Institute of the McGill University Health Centre. Primary endpoint: Maximum tolerable dose. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
sildenafil
03
Conditions
hypoxic-ischemic encephalopathy (HIE)asphyxia neonatorum
Beyond the preview
Go deeper on PACTR202202647130754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202202647130754.